Crossmark

Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study

Crossref DOI link: https://doi.org/10.1186/s12885-025-14834-1

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shin, Ji Eun

Park, Sehhoon

Jung, Hyun Ae

Sun, Jong-Mu

Lee, Se-Hoon

Ahn, Jin Seok

Ahn, Myung-Ju
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 6 February 2025

Accepted: 8 August 2025

First Online: 21 October 2025

Declarations

:

: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (as revised in 2013). This study was approved by the Institutional Review Board of the Samsung Medical Center with a waiver for informed consent (Institutional Review Board no. 2024-02-123).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below